Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 49-55 , March 2007

Myelodysplasia: The good, the fair and the ugly

  • Charles A. Schiffer, MD (Professor of Medicine and Oncology Head, Leukemia/Lymphoma Multidisciplinary Team)

      Affiliations

    • Corresponding Author InformationTel.: +1 313 576 8737.

References 

  1. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Annals of Internal Medicine. 2002;137:156–163
  2. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. British Journal of Haematology. 1997;99:699–705
  3. Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 2006;91:667–670
  4. Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia. 2004;18:460–465
  5. Yazji S, Giles F, Kantarjian H, et al. Antithymocyte globulin (ATG) based therapy in patients with myelodysplastic syndrome (MDS). Blood. 2002;100:794a;(abstract 3135)
  6. Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. British Journal of Haematology. 2003;120:679–684
  7. Steensma DP, Dispenzieri A, Moore SB, et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2003;101:2156–2158
  8. Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood. 2002;100:3639–3645
  9. List A, Dewald G, Bennett J, et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England Journal of Medicine. 2006;355:1456–1465
  10. Raza A, Reeves J, Feldman E, et al. Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities. Blood. 2006;108:78a;(abstract 250)
  11. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced intensity conditioning and conventional high dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–846
  12. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 1998;12(supplement 1):S25–S29
  13. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology. 2002;20:2429–2440
  14. Silverman LR, McKenzie DR, Peterson BL, et al. Cancer and Leukemia Group B Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Journal of Clinical Oncology. 2006;24:3895–3903
  15. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803
  16. Kantarjian H, Oki Y, Garcia-Manero G et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood [in press].

PII: S1521-6926(06)00089-2

doi: 10.1016/j.beha.2006.12.001

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 49-55 , March 2007

Article Tools